68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer
Authors:
- Christos SachpekidisCSChristos Sachpekidis
- Klaus KopkaKlaus Kopka
- Matthias EderMEMatthias Eder
- Boris A. HadaschikBHBoris A. Hadaschik
- Martin T. FreitagMFMartin T. Freitag
- Leyun PanLPLeyun Pan
- Uwe HaberkornUHUwe Haberkorn
- Antonia Dimitrakopoulou-StraussAntonia Dimitrakopoulou-Strauss
- 1 November 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 41 (11) , e473-e479
Abstract
The aim of our study is to assess the pharmacokinetics and biodistribution of 68Ga-PSMA-11 in patients suffering from primary prostate cancer (PC) by means of dynamic and whole-body PET/CT. Twenty-four patients with primary, previously untreated PC were enrolled in the study. All patients underwent dynamic PET/CT (dPET/CT) scanning of the pelvis and whole-body PET/CT studies with 68Ga-PSMA-11. The evaluation of dPET/CT studies was based on qualitative evaluation, SUV calculation, and quantitative analysis based on two-tissue compartment modeling and a noncompartmental approach leading to the extraction of fractal dimension (FD). A total of 23/24 patients (95.8%) were 68Ga-PSMA-11 positive. In 9/24 patients (37.5%), metastatic lesions were detected. PC-associated lesions demonstrated the following mean values: SUVaverage = 14.3, SUVmax = 23.4, K1 = 0.24 (1/min), k3 = 0.34 (1/min), influx = 0.15 (1/min), and FD = 1.27. The parameters SUVaverage, SUVmax, k3, influx, and FD derived from PC-associated lesions were significantly higher than respective values derived from reference prostate tissue. Time-activity curves derived from PC-associated lesions revealed an increasing 68Ga-PSMA-11 accumulation during dynamic PET acquisition. Correlation analysis revealed a moderate but significant correlation between PSA levels and SUVaverage (r = 0.60) and SUVmax (r = 0.57), and a weak but significant correlation between Gleason score and SUVaverage (r = 0.33) and SUVmax (r = 0.28). 68Ga-PSMA-11 PET/CT confirmed its capacity in detecting primary PC with a detection rate of 95.8%. Dynamic PET/CT studies of the pelvis revealed an increase in tracer uptake in PC-associated lesions during the 60 minutes of dynamic PET acquisition, a finding with potential applications in anti-PSMA approaches.Keywords
This publication has 36 references indexed in Scilit:
- Diagnostic Efficacy of 68 Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate CancerJournal of Urology, 2016
- Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancerCA: A Cancer Journal for Clinicians, 2015
- Prostate-Specific Antigen and Prostate-Specific Antigen Velocity as Threshold Indicators in 11C-Acetate PET/CTAC Scanning for Prostate Cancer RecurrenceClinical Nuclear Medicine, 2014
- Limited evidence for the use of imaging to detect prostate cancer: A systematic reviewEuropean Journal of Radiology, 2014
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013European Urology, 2014
- Choline PET or PET/CT and Biochemical Relapse of Prostate CancerClinical Nuclear Medicine, 2013
- Prostate-specific membrane antigen-based imagingUrologic Oncology: Seminars and Original Investigations, 2013
- Role of 18F-Choline PET/CT in Biochemically Relapsed Prostate Cancer After Radical ProstatectomyClinical Nuclear Medicine, 2013
- Imaging in Prostate Cancer Staging: Present Role and Future PerspectivesUrologia Internationalis, 2012
- Unnecessary Imaging for the Staging of Low-risk Prostate Cancer Is CommonUrology, 2011